Prevalence of factor VIII inhibitor in patients with hemophilia A in Sanandaj

Farzad Company; Nazila Rezaei; Mariam Aliasgharpoor

Journal of Kermanshah University of Medical Sciences

Peer-reviewed Medical Quarterly

Current Issue All Issues In Press Accepted Manuscripts Search

Journal Information Boards and Committees Indexing and Listing Sources Journal Metrics Open Peer Review (OPR)Publication Ethics and Malpractice Statement Reviewer and AE Registration Form Contact Us Support

Authors Guide Submit Manuscript

Prevalence of factor VIII inhibitor in patients with hemophilia A in Sanandaj

Author(s):

Farzad Company^1,*,

Nazila Rezaei¹,

Mariam Aliasgharpoor¹

1Dept. of Haematology & Oncology, School of Medicine, Kurdistan University of Medical Science. Sanandaj, Iran

Journal of Kermanshah University of Medical Sciences:Vol. 15, issue 2; e79379

Published online:Jul 19, 2011

Article type:Research Article

Received:Apr 13, 2010

Accepted:Aug 03, 2010

How to Cite:Farzad CompanyNazila RezaeiMariam AliasgharpoorPrevalence of factor VIII inhibitor in patients with hemophilia A in Sanandaj.J Kermanshah Univ Med Sci.15(2):e79379.

Abstract

Background: Factor VIII inhibitor is one of the most problems in the treatment of hemophilia. Patients with hemophilia who have inhibitors are capable of severe hemorrhage and treatments of these patients are more expensive and more difficult than those patients without inhibitor. The aim of present study was to determine the prevalence of inhibitor and to assess the necessity of screening of the factor VIII inhibitors in hemophilia patients.

Methods: 104 patients with hemophilia A referred to Besat Hospital of Sanandaj during 2006-2009 were evaluated for inhibitors against factor VIII using convenient sampling method. Their venous blood samples were mixed in a proportion of 9 to 1 with 3.2g/dl citrate sodium. After preparation of plasma APTT mix test and then Bethesda test followed by determination of inhibitor were performed.

Results: The mean age of subjects was 23.8-±9.3 year. Twenty out of 104 patients with hemophilia A (19.2%) had inhibitor factor VIII. None of patients were assayed for inhibitor previously. Sixteen patients were low responder and four patients showed high responder with the Bethesda inhibitor level above five unit. Higher levels of inhibitor were existed in 11-25 years old age groups. There was no significant relationship between factor VIII inhibitor and patient's age.

Conclusion: Regarding to high prevalence of the factor VIII inhibitor in these patients, screening all hemophilia A patients every 6 months and doing Bethesda test for new identified cases with this inhibitor is highly recommended.

Keywords

hemophilia A

factor VIII inhibitor

screening

Fulltext

References

1.
The references of this article is available on PDF.

comments